AIM - AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents | Benzinga
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039
Management discusses patent issuance and what this means in a brief video: here
OCALA, Fla., Nov. 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No. 11,813,279 and 11,813,281 for Ampligen® titled "Compositions for cancer therapy and methods," and "Methods for improving exercise tolerance in myalgic encephalomyelitis patients," respectively.
AIM Chief Executive Officer Thomas K. Equels stated: "Our ongoing effort to expand and solidify AIM's global intellectual property estate is a foundational component of our development strategy for Ampligen. AIM's expectation for Ampligen — both as a therapeutic for people suffering from dire diseases and as a valuable asset for our stockholders — is the driving force behind our multiple clinical studies in oncology, ME/CFS and Post-COVID conditions. These two new U.S. patents will serve to further strengthen the potential financial future of our company by extending certain sole rights to Ampligen and for these uses to 2039."
Click here to watch a brief video from the AIM management team discussing the issuance of the U.S. patents and what it means for the pipeline development strategy for Ampligen®.
Oncology Patent
The new patented methods involve the administration of a unique combination of two compounds to patients suffering from pancreatic cancer, renal cell carcinoma, colorectal cancer and/or melanoma. The first compound is an anti-PD-L1 antibody and the second compound is Ampligen. The combination of ...